CTLA4 and cancer: Among cancer therapies, immune checkpoint inhibition using antibodies against programmed cell death protein 1 (PD-1), PD-1 ligand (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has led to impressive clinical responses in patients.